Evidence map›Paper›PMID 40013033›Full record

ArticleFrontiers in public health2025

Trend of skin cancer mortality and years of life lost in China from 2013 to 2021.

Jingyi Li, Jiaqi Zeng, Yuanchao Yang, Biran Huang

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingyi LiDepartment of Dermatology, Huizhou First Hospital, Huizhou, China.
Jiaqi ZengDepartment of Dermatology, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.
Yuanchao YangDepartment of Dermatology, Huizhou First Hospital, Huizhou, China.
Biran HuangDepartment of Dermatology, Huizhou First Hospital, Huizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The mortality rates of skin cancer in Chinese population are increasing. However, research on skin cancer trends in China is limited. This study aimed to estimate the mortality trends of skin cancer in China within 2013-2021. Methods: A retrospective analysis of skin cancer deaths within 2013-2021 was performed using the China death cause surveillance dataset compiled by the National Health Commission Statistics Information Center and the China Center for Disease Control and Prevention Chronic Non-Communicable Diseases Prevention and Control Center. The mortality rates of skin cancer were stratified by gender, age group, and area (urban or rural). Results: From 2013 to 2021 in China, the crude mortality rate (CMR) of skin cancer increased, and the age-standardized mortality rate (ASMR), and age-standardized years of life lost (YLL) rate decreased. The ASMR and age-standardized YLL rate were 0.85/100,000 and 18.95/100,000 in 2013, respectively, and decreased to 0.75/100,000 and 16.84/100,000, respectively, in 2021. From 2013 to 2021, the CMR, ASMR, and age-standardized YLL rate of skin cancer were higher in males than in females and higher in rural areas rather than in urban ones. In terms of the highest age-specific mortality rate, it appeared in the age group of over 85 years old. Conclusion: The burden of skin cancer remained heavily from 2013 to 2021 in China. Especially males, older adult, and rural residents had higher mortality. Thus, effective measures and strategies should be taken to reduce the incidence and mortality of skin cancer.

Indexed as

Life ExpectancySkin NeoplasmsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolChinaFemaleHumansInfantMaleMiddle AgedMortalityRetrospective StudiesChinadisease burdenmortality rateskin canceryears of life lost

Identifiers

PMID40013033
PMCPMC11861555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.